Skyrizi came out on top with the latest quarterly crown for over-the-counter (OTC) pharma and Rx brands. The AbbVie treatment for psoriasis, Crohn’s disease and psoriatic arthritis finished in first ...
As we hit the middle of the year, AbbVie is comfortably back in the top TV drug ad spenders’ driving seat taking the top two spots in July with its immunology blockbuster duo Skyrizi and Rinvoq, ...
Skyrizi finished atop the Rx and over-the-counter (OTC) pharma brand ad rankings in August, according to data released by iSpot.tv on Wednesday afternoon. Skyrizi generated an impressions share of ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of January ...
Investor's Business Daily on MSN
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
AbbVie stock popped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, ...
AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...
Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback